Shots:
- The CHMP has recommended AVT06, a biosimilar version of Eylea (aflibercept 2 mg), across all 30 EEA states
- AVT06 is a recombinant fusion protein that inhibits VEGF to reduce neovascularization and vascular permeability. The CHMP recommends MAA for wet AMD, visual impairment from macular oedema due to RVO (branch or central), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV)
- Alvotech develops and supplies biosimilars, while Advanz Pharma handles registration and has exclusive commercialization rights in most EU countries. Advanz also holds distribution rights for AVT29, Alvotech’s proposed biosimilar to Eylea HD (aflibercept 8 mg), in the same region
Ref: Globenewswire | Image: Alvotech & Advanz | Press Release
Related News:- Alvotech Expands its Partnership with Advanz Pharma to Commercialize Three Additional Biosimilars in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
